Valuation dashboard for Cencora, Inc. (COR) with P/E 24.58, P/B 20.94, EV/EBITDA 13.99 and dividend yield 0.73%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment.
Analysis Summary
Cencora, Inc. reported revenue of $321.33B in the most recent fiscal year, growing at a 5-year CAGR of 11.1%.
Trailing-twelve-month margins: gross margin 3.7%, operating margin 1.3%, net margin 0.8%.
At $330.84 (closing price, October 30, 2026), COR trades at a P/E of 24.58 and an ROE of 106.43%. Market capitalisation stands at $63.1B, placing it among large-cap names.
Balance sheet quality for COR: current ratio of 0.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 24.58 |
| Price / Book | 20.94 |
| EV / EBITDA | 13.99 |
| Dividend Yield | 0.73% |
Valuation Models
| DCF Fair Value | $551.59 |
| vs Current Price | +66.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| COR | Cencora, Inc. | $63.1B | 24.58 | 20.94 | 106.4% |
| HSIC | Henry Schein, Inc. | $9.5B | 24.75 | 3.05 | 12.4% |
| MCK | McKesson Corporation | $116.0B | 26.61 | -194.4% | |
| CAH | Cardinal Health, Inc. | $58.0B | 34.64 | -59.7% | |
| 0JZU.L | McKesson Corporation | $117.5B | 26.67 | -194.4% | |
| 0HF3.L | Cencora, Inc. | $63.6B | 24.48 | 20.95 | 106.4% |
| 0HTG.L | Cardinal Health, Inc. | $58.9B | 34.33 | -59.7% | |
| 0L3C.L | Henry Schein, Inc. | $9.4B | 24.55 | 3.05 | 12.4% |
Price
| Price | $330.84 (closing price, October 30, 2026) |
| Market Cap | $63.1B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 106.43% |
| Return on Invested Capital | 12.75% |
| Return on Assets | 3.13% |
| Gross Margin | 3.71% |
| Operating Margin | 1.30% |
| Net Margin | 0.79% |
Related companies: HSIC · MCK · CAH · 0JZU.L · 0HF3.L · 0HTG.L · 0L3C.L · 0ROG.L
Explore sector: Healthcare · Medical - Distribution
More sections of COR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks